LARISSA II

Larissa ii email format

Verified email-pattern data for Larissa Ii is currently limited. You can still use the company insights and contact sections below.
We are a consortium of six partners with a single goal: the development and evaluation of a vaccine for the prevention of Rift Valley fever in humans. The project is named "LARISSA", acronym for Live Attenuated Rift Valley Fever Vaccine for Single Shot Application. Our hRVFV-4s candidate vaccine has been evaluated for safety and immunogenicity in a First in Human (FIH) Phase I study in Belgium in the LARISSA I project. The Phase II development is currently ongoing in our LARISSA II project, which is financed by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the EU Horizon Europe programme. CEPI aims to accelerate the development of vaccines against emerging infectious diseases and to enable equitable access to these vaccines in the face of outbreaks.

Company Details

Employees
1
Founded
-
Industry
Biotechnology Research
Looking for a particular LARISSA II employee's phone or email?

Larissa Ii Questions

Explore related pages

Related company profiles:

Top LARISSA II Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant